Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nuvo Research Receives €4.4 Million Additional Funding to Develop WF10

Published: Thursday, December 27, 2012
Last Updated: Thursday, December 27, 2012
Bookmark and Share
Total cost of the development program is estimated to be €6.3 million.

Nuvo Research Inc. has announced that the Development Bank of Saxony (SAB) in Germany has agreed to provide Nuvo with up to €4.4 million of funding for the further development of its improved reformulated version of WF10 (Reformulated WF10).

The funding will take the form of a non-repayable reimbursement of specific development monies expended by Nuvo until July 2014.

The SAB funding will be used to support CMC activities, "in vitro" experiments and a number of preclinical studies relating to Reformulated WF10 for which Nuvo filed a US provisional patent in December 2011.

These studies are being conducted by Nuvo in partnership with the University of Leipzig and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig.

The total cost of this development program is estimated to be €6.3 million and the SAB committed to provide up to €4.4 million in funding to support these projects.

Nuvo will have certain contractual obligations to the SAB including the obligation to provide matching funding from its own resources of €1.9 million over the two year period ending in July 2014.

Nuvo will own or have exclusive global rights to commercially exploit all WF10 related intellectual property that comes from the funded projects.

In the fall of 2009, the SAB committed to provide funding over a three-year period of approximately €2.2 million for two WF10 development projects.

With the most recent commitment from the SAB, the total funding is approximately €6.6 million towards a €10.8 million development program.

"We are thrilled to expand our existing partnership with the SAB, the University of Leipzig and the Fraunhofer Institute by securing SAB funding that will allow us to continue with the development of WF10," said Dr. Henrich Guntermann, President of Nuvo's Immunology Group.

Dr. Guntermann continued, "WF10 is an extremely exciting compound with the potential to treat a broad range of medical conditions. We are pleased that the SAB recognizes WF10's potential and has chosen to partner with Nuvo."

Nuvo believes that WF10 has the potential to treat a wide range of medical conditions including auto immune disorders.

In 2010, Nuvo announced that its European Phase 2 clinical trial evaluating WF10 as a treatment for severe allergic rhinitis met its primary and secondary end points with a p-value of less than 0.001.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nuvo Research Announces 2013 Fourth Quarter & Year-End Results
Company will commence a Phase 2 study of WF10 with results expected in Q4 2014.
Friday, March 07, 2014
Nuvo Research Announces Scientific Presentation at the Annual Meeting of AAI
Data evaluating WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice.
Friday, May 17, 2013
Scientific News
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos